BACKGROUND: Large epidemiologic studies have reported the premature onset of age-related conditions, such as ischemic heart disease and diabetes mellitus, in childhood cancer survivors, decades earlier than in their peers. The authors investigated whether young adult survivors of childhood acute lymphoblastic leukemia (ALL) have a biologic phenotype of cellular ageing and chronic inflammation. METHODS: Plasma inflammatory cytokines were measured using a cytometric bead array in 87 asymptomatic young adult survivors of childhood ALL (median age, 25 years; age range, 18-35 years) who attended annual follow-up clinic and compared with healthy, age-matched and sex-matched controls. Leukocyte telomere length (LTL) was measured using Southern blot analysis. RESULTS: Survivors had significant elevation of plasma interleukin-2 (IL-2), IL-10, IL-17a, and high-sensitivity C-reactive protein levels (all P <.05). A raised high-sensitivity C-reactive protein level (>0.8 mg/dL) was related to increased odds of having metabolic syndrome (odds ratio, 7.256; 95% confidence interval, 1.501-35.074). Survivors also had significantly shorter LTL compared with controls (median, 9866 vs 10,392 base pairs; P 5.021). Compared with published data, LTL in survivors was similar to that in healthy individuals aged 20 years older. Survivors who received cranial irradiation had shorter LTL compared with those who had not (P 5.013). CON-CLUSIONS: Asymptomatic young adult survivors of childhood ALL demonstrate a biologic profile of chronic inflammation and telomere attrition, consistent with an early onset of cellular processes that drive accelerated aging. These processes may explain the premature development of age-related chronic conditions in childhood cancer survivors. Understanding their molecular basis may facilitate targeted interventions to disrupt the accelerated aging process and its long-term impact on overall health. Cancer 2017;123:4207-14.
INTRODUCTION
Progress in the treatment of childhood cancers is 1 of the great success stories of modern medicine, with current overall cure rates exceeding 75% for many cancer types. 1 Even countries with limited resources have recorded improved outcomes; for example, a 6-year survival rate of 81% was recently reported for Malaysian children with acute lymphoblastic leukemia. 2 However, epidemiologic studies in survivors reveal that adults treated for cancer during childhood are at increased risk of a premature onset of chronic, age-related health conditions 3, 4 ; frequent hospitalization 5 ; and early mortality 6 independent of organ-specific, treatment-related toxicities. The early development of chronic diseases among childhood cancer survivors is particularly striking; notably, data from the Childhood Cancer Survivor Study demonstrated similar cumulative incidence rates of chronic health conditions in childhood cancer survivors aged 24 years and their older siblings (aged 50 years). 3 Although several studies have described a phenotype of accelerated aging in childhood cancer survivors (eg, premature development of ischemic heart disease 7, 8 and frailty 9 ), the understanding of this phenomenon at a cellular level remains limited. Aging is a complex, time-related process characterized by the accumulation of molecular, metabolic, and physical changes in an individual. Hallmarks of aging at the cellular and tissue levels involve 3 main components: 1) accumulation of unrepaired DNA damage and telomere shortening, causing cellular senescence; 2) impaired cell and tissue renewal because of depletion of stem cells as well as progenitor cell pools; and 3) chronic, systemic inflammation.
A pervasive feature of most, if not all, age-related diseases is chronic inflammation in the absence of overt infection, for which the term "inflammaging" has been coined. 10 This age-related inflammatory condition involves local events and systemic activation of both innate and adaptive immune systems, in which T-cell functional alterations are the most significant features of immunosenescence. 12 In general, during the activation of adaptive immunity, naive CD4-positive T cells can differentiate into distinct lineages of T-helper (Th) cells with different immunologic functions, namely, Th1, Th2, Th17, and regulatory T (Treg) cells. Th1 cell polarization (type 1 response) is dominated by increased production of the cytokines interleukin (IL-2) and interferon gamma (IFN-c) and elicits cell-mediated immunity against intracellular pathogens. A type 2 response, mediated by Th2 cells and characterized by elevated levels of IL-4, IL-5, and IL-10, is involved in the immune response against extracellular parasites and allergens. The relative contribution of these different cytokines determine the patterns of immuno-inflammatory response by counter-regulating each other. 13 In particular, IL-17, which is produced by activated Th17 cells, enhances T-cell priming and stimulates fibroblasts, endothelial cells, macrophages, and epithelial cells to produce multiple proinflammatory mediators, including IL-1, IL-6, tumor necrosis factor alpha (TNF-a), nitric oxide synthase 2 (NOS-2), metalloproteases, and chemokines, resulting in the induction of inflammation.
14 IL-17 expression is increased in patients with a variety of allergic and autoimmune conditions, whereas such conditions are suppressed in IL-17-deficient (IL-17 -/-) mice. 15 Telomeres are specialized, protective DNA-protein structures located at the end of eukaryotic chromosomes, which progressively shorten with each cell division and eventually reach a critical threshold, leading to either cellular senescence or apoptosis. Telomere length is widely considered a surrogate marker of aging, and telomere shortening has been correlated with an increased risk of age-related diseases, in which chronic inflammation plays a prominent role. 16 In addition, studies in murine models have also demonstrated the role of chronic inflammation in telomere dysfunction and accelerated aging. 17 We previously reported evidence of early senescence in immune cells from young adult survivors of childhood leukemia, where higher proportions of their CD4-positive and CD8-positive T cells expressed late differentiation markers (CD57-positive/CD28-negative) compared with controls. 18 Expanding the same cohort, the current study provides evidence supporting a chronic inflammatory state and associated telomere attrition as additional features of accelerated aging in these survivors. Understanding the biologic mechanisms driving the development of age-related morbidities in cancer survivors may facilitate the development of targeted interventions to disrupt these processes.
MATERIALS AND METHODS

Participants
Survivors of childhood ALL (diagnosed before age 18 years) who were in continuous clinical remission and were attending an annual follow-up clinic at the University Malaya Medical Center in Kuala Lumpur, Malaysia, were recruited. All survivors were symptom-free. Perturbations in their health status were only derived from physical examination or a blood test. Inclusion criteria for survivors were ages 18 to 35 years who had ceased treatment more than 5 years before the start of the study. Those who had undergone bone marrow transplantation, were pregnant, or had received vaccination in the preceding 6 months were excluded. Chemotherapy regimens for ALL followed the protocols used in the institution at different time periods between 1985 and 2010 but were largely based on either the Berlin-Frankfurt-Munich-ALL85, Berlin-Frankfurt-Munich-ALL95, Dutch Childhood Oncology Group-ALL7, or the Malaysia-Singapore ALL 2003 protocols.
2 Seventy-six survivors in this cohort had participated in an earlier study of immune senescence. 18 A control group was constituted from age-matched and sexmatched volunteers using the same selection criteria for survivors except for history of cancer. To minimize "healthy control" bias, our controls were assembled from a heterogenous group of individuals from diverse socioeconomic backgrounds and lifestyles. In addition to family members of participants, they included university students and nurses as well as janitorial and general workers at the hospital. All participants provided written informed consent and agreed to the release of medical record information. The study was approved by the Institutional Review Board of the University Malaya Medical Center, Kuala Lumpur (MEC 2014-1093.65 and 2016101-4309).
Measurement of Inflammatory Cytokines
Plasma was isolated from peripheral blood collected in ethylenediaminetetraacetic acid tubes and stored at 280 8C until analysis. Plasma concentrations of Th1 (IL-2, TNF-a, IFN-c), Th2 (IL-4, IL-6, IL-10) and Th17 (IL-17A) cytokines were determined at 1:2 dilution ratio using a BD Cytometric Bead Array Human Th1/Th2/ Th17 Cytokine Kit (BD Biosciences, San Diego, CA).
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The fluorescence produced by cytometric array beads was measured on a FACSCanto II flow cytometer and was analyzed using FCAP Array software (version 1; BD Biosciences). The detection limits for these cytokines were 2.6 pg/mL for IL-2, 3.8 pg/mL for TNF-a, 3.7 pg/mL for IFN-c, 4.9 pg/mL for IL-4, 2.4 pg/mL for IL-6, 4.5 pg/ mL for IL-10, and 18.9 pg/mL for IL-17A. The concentration of each cytokine below the detection limit was recorded as 0. Cytokine levels were interpreted as increased or decreased compared with the median values in the controls. 19 All procedures were carried out according to the manufacturers' instructions.
Measurement of Telomere Length
Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA kit (Qiagen GmbH, Hilden, Germany). Nontelomeric DNA was digested to low-molecular-weight fragments by specific restriction enzymes, leaving telomeric DNA and subtelomeric DNA intact (TeloTAGGG Telomere Length Assay; Roche GmbH, Mannheim, Germany). DNA fragments were then separated by gel electrophoresis before being transferred onto a nylon membrane by Southern blot analysis. The blotted DNA fragments were hybridized to a digoxigenin-labeled probe specific for telomeric repeats (TTAGGG) and incubated with a digoxigenin-specific antibody (TeloTAGGG Telomere Length Assay; Roche GmbH). The blots were imaged using a gel documentation system (Biospectrum 410; UVP, LLC, Upland, CA), and leukocyte telomere length (LTL) was analyzed using TeloTool software. 20 Samples that had LTL within the lower tertile of control length were reported as having short telomeres, as previously described. 21 
Biochemical Parameters and Metabolic Risk Factors
Complete blood counts, liver and renal function assays, lipid profiles, glycosylated hemoglobin levels, and highsensitivity C-reactive protein (hsCRP) levels were measured by the hospital's diagnostic laboratory within 4 hours of venipuncture. An elevated hsCRP level was defined as 0.8 mg/dL, ie, twice the upper limit of normal value, in our diagnostic laboratory. Metabolic syndrome was defined as the presence of at least 3 of the following metabolic risk factors 22 : fasting blood glucose > 6.1 mmol/L, hypertension (systolic blood pressure > 130 mm Hg or diastolic blood pressure >85 mm Hg), hypertriglyceridemia (serum triglycerides > 1.7 mmol/L), low high-density lipoprotein (men, < 1.03 mmol/L; women, < 1.29 mmol/L), and a large waistline (men, > 102 cm; women, > 88 cm).
Statistical Analysis
Because metabolic derangements have a known causeeffect relation with chronic inflammation, both survivors and controls with metabolic syndrome were excluded from the statistical analyses to remove bias. Comparisons between groups for continuous variables were assessed using the Mann-Whitney U test, and correlations were assessed using Spearman correlation (q). An analysis of covariance was performed to investigate the differences of cytokine concentrations and telomere length between survivors and controls after adjusting for covariates (age, sex, and smoking status). Logistic regression was used to test whether the inflammatory markers would be associated with increased odds of having metabolic syndrome. All analyses were performed using IBM SPSS Statistics version 20 (IBM Corporation, Armonk, NY). The power of hypertension (systolic blood pressure > 130 mm Hg or diastolic blood pressure >85 mm Hg), hypertriglyceridemia (serum triglycerides > 1.7 mmol/L), low high-density lipoprotein (men, < 1.03 mmol/L; women, < 1.29 mmol/L), and a large waistline (men, > 102 cm; women, > 88 cm).
our study was 94% with a Type I error rate of 5%, based on a standard deviation of hsCRP reported in a previous study 23 of 0.354 and a true difference of means in 87 survivors and 87 controls of 0.19.
RESULTS
Survivors
Eighty-seven young adult survivors of childhood ALL and 87 age-matched controls were recruited. Clinical characteristics are listed in Table 1 
Inflammatory Cytokines
After adjustment for sex and smoking status, plasma levels of IL-2, IL-10, IL-17A, and hsCRP in survivors were significantly higher compared with the levels in healthy controls (all P < .05) (Fig. 1A,F,G,H) . The median plasma levels of IL-4, IL-6, TNF-a, and IFN-c in survivors were higher than those in controls, but the difference between groups was not statistically significant ( Fig. 1B-E ).
Telomere Length
Survivors had significantly shorter LTL compared with controls (median, 9866 vs 10,392 base pairs [bp]; P 5 .021) (Fig. 2A) . The median LTL in survivors who received cranial radiotherapy was 9765 bp compared with 10205 bp in those who did not (P 5 .013) (Fig. 2B) . We were not able to analyze the impact of anthracyclines or alkylators on telomere length, because >70% of survivors had been exposed to these agents. Fifty-six percent of survivors were diagnosed aged at age 5 years. The median LTL in this subgroup was 9767 bp compared with 10468 bp in those who were diagnosed at age >5 years (P 5 .043) (Fig. 2C) . Elevated hsCRP was inversely correlated with LTL (q 5 20.25; P 5 .037) but there was no significant association between LTL and the other inflammatory biomarkers.
Clinical Value of Inflammatory Biomarkers
We further investigated the potential role of measuring inflammatory biomarkers in the clinical management of asymptomatic childhood cancer survivors who attended health surveillance clinics. In survivors, elevated hsCRP was identified as an indicator for metabolic syndrome (odds ratio, 7.256; 95% CI, 1.501-35.074; P 5 .014) ( Table 2 ). In contrast, elevated hsCRP in controls did not confer an increased odds of having metabolic syndrome.
We were unable to demonstrate a significant association between the other plasma cytokines or short LTL (9822 bp) with metabolic syndrome.
DISCUSSION
We report significant elevation of plasma Th1, Th2, and Th17 cytokines (namely IL-2, IL-10, and IL-17A) as well as hsCRP in childhood ALL survivors compared with peers who had no history of cancer. The mechanisms responsible for these changes in proinflammatory cytokines remain to be identified. Elevated plasma levels of IL-17A, as observed in our survivor group, suggest microbial dysbiosis as 1 of the plausible mechanisms promoting chronic inflammation. Many of our survivors experienced chemotherapy-induced mucositis, had repeated episodes of febrile neutropenia, and received multiple courses of broad-spectrum antibiotics during the 2 years of leukemia therapy, all of which could profoundly and durably alter Figure 2 . Analysis of covariance was applied to measure the difference in leukocyte telomere length (LTL) in base pairs (bp) between groups, adjusting for significant covariates. LTL is illustrated (A) in survivors and age-matched controls; (B) in survivors who received (n 5 42) and did not receive (n 5 45) cranial irradiation ( 1 and -radiotherapy, respectively); and (C) in survivors who were diagnosed for leukemia at age 5 years (n 5 50) or age > 5 years (n 5 37). P values < .05 were considered statistically significant (marked with an asterisk). Bars indicate medians and interquartile ranges. normal gut flora. 24 Perturbation in the microbiome has been implicated as a source of chronic inflammation in patients with human immunodeficiency virus, 25 even after immune reconstitution; and a similar phenomenon was recently reported in our cohort of childhood cancer survivors. 26 In an earlier study using the same cohort, we reported a significantly higher proportion of latedifferentiated CD4-positive and CD8-positive T lymphocytes compared with age-matched controls. 18 The current study, with additional survivors and controls, provides further evidence of accelerated cellular aging by demonstrating that survivors have significantly shorter LTL compared with controls.
Studies on age-dependent attrition of telomere length in human leukocytes have demonstrated that the rate of telomere shortening is rapid in the first few years of life but subsequently declines considerably, resulting in a plateau in telomere length during later adulthood. 27, 28 Rapid LTL attrition during early life is believed to be the consequence of extensive expansion of hematopoietic stem cell and progenitor cell pools involving both symmetric and asymmetric cell divisions. 29 Compared with previously published LTL data, albeit in Caucasian populations, the median LTL of our healthy controls was similar to individuals in the group ages 20 to 36 years, corresponding to the median age from the previous data. 27 However, LTL in our leukemia survivors mirrored the measurements of those in the group ages 42 to 72 years and was compatible with a recent study in Finnish long-term survivors of neuroblastoma. 30 These observations are suggestive of premature replicative senescence in leukocytes of the survivors, highlighting an accelerated exhaustion of the pool of hematopoietic stem/progenitor cells.
The augmented inflammatory phenotype observed in childhood leukemia survivors may accelerate leukocyte telomere attrition by promoting rapid cell turnover and/ or by inducing release of reactive oxygen species, which in turn, leads to direct damage to telomeric DNA through oxidative stress or inhibition of telomerase activity. 13, 31 Feeding into this vicious cycle, the accumulation of senescent cells with critically short LTL may also produce many proinflammatory cytokines, a phenomenon called "senescence-associated secretory phenotype," which further contributes to an increased inflammatory load. 32, 33 The causes of accelerated cellular aging observed in this study remain to be elucidated. A common hypothesis is that therapy-induced damage to normal cells leads to systemic chronic inflammation, subsequent telomere attrition, and premature aging in cancer survivors, irrespective of age. In an 18-month longitudinal follow-up study of 209 breast cancer survivors (mean age, 55 years), Alfano et al reported significantly elevated TNF-a and IL-6 with associated accumulation of comorbidities, suggestive of an aging phenotype. 34 We speculate that the collateral cellular damage induced by cancer and its treatment may be more pronounced in children because these insults occur within a developmental window of high sensitivity, especially as telomere attrition occurs at its highest rate during the first few years of life. 27, 35 Notably, our survivors who were diagnosed at a younger age had significantly shorter LTL compared with those who were diagnosed after the age of 5 years.
In addition, social, traumatic, and psychological experiences associated with having cancer in childhood may become embedded epigenetically and lead to longterm, or even permanent, alterations in gene expression. 36, 37 It has been demonstrated that adverse life events at a young age increase the odds of short telomeres; in contrast, comparable experiences in adults have not demonstrated a similar biologic impact. 38 The current study has several limitations. First, temporal changes in the survivors' clinical or biochemical parameters could not be assessed, because only crosssectional data were available. Second, the cytometric beads array assay used to measure plasma levels of the various cytokines may not be sensitive enough to detect low levels, especially in controls. Third, the sample size was not large enough to enable a detailed analysis of the effects of previous treatment, except for radiotherapy. Finally, there is a possibility that the findings are because of chance, given that the comparisons were not adjusted for multiplicity. Notwithstanding these limitations, our findings provide strong evidence of accelerated cellular aging in childhood survivors of cancer. Although they were predominantly in their mid-20s and were asymptomatic, our leukemia survivors had a cellular phenotype similar to that observed in individuals 2 to 3 decades older.
Currently, 1 in 5 of our survivors has developed overt metabolic syndrome, whereas one-half are already demonstrating at least 1 abnormal biochemical parameter. It will be very important to continue follow-up of these survivors to allow documentation of further changes in their health, especially the development of metabolic comorbidities. Our data exhibit the discerning capability of hsCRP as a statistically robust inflammatory biomarker associated with metabolic syndrome in childhood cancer survivors. Although we were not able to replicate this association in the control group because of their low Original Article prevalence of metabolic syndrome, the findings do suggest that hsCRP may have clinical utility in health surveillance for childhood cancer survivors. Intuitively, we recommend that lifestyle and/or pharmacologic interventions should be implemented well before the onset of clinical signs.
In conclusion, we observed that, compared with peers of the same age without cancer, young adult survivors of childhood leukemia have evidence of cellular aging that may predispose them to develop debilitating chronic conditions at earlier than expected ages. This study also provides important baseline data for future interventional studies that aim to control or reverse the systemic inflammation, telomere attrition, and increased immunosenescence observed in these survivors.
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